Joanna Kośka

Joanna Kośka

Auto-generated profile, based on publicly available information

Joanna Kośka

Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KDKacper Dywan
Kacper Dywan
JKJoanna Kośka
Joanna Kośka
GŁGabriela Łocik
Gabriela Łocik
KMKatarzyna Moliszewska
Katarzyna Moliszewska
PKPaweł Kukiełka
Paweł Kukiełka
MBMichał Błaszkiewicz
Michał Błaszkiewicz
Introduction and Purpose: Plantar fasciitis (PF) is one of the most common causes of heel pain in adults, with a lifetime incidence of about 10%. Diagnosis is primarily clinical, based on patient history and physical examination. This study aims to present and compare treatment modalities for PF, including conservative and surgical options. Brief Description of the State of Knowledge: The plantar fascia is a dense connective tissue crucial for supporting the medial longitudinal arch and enabling efficient gait. PF most often affects individuals aged 45–65 and is frequently associated with elevated body mass index. A characteristic symptom is sharp heel pain upon rising in the morning, which improves with walking. Physical examination may include the Silfverskiöld test to assess gastrocnemius contracture. Imaging, such as radiography, ultrasonography, or MRI, can support diagnosis. Although PF often recurs, 85–90% of patients respond to conservative treatment. Historically, management relied on night splints, orthoses, NSAIDs, and corticosteroid injections. Current strategies emphasize stretching and strengthening exercises. Surgical treatment is reserved for refractory cases. Materials and methods: In this article, we utilized scientific literature describing various treatment approaches for patients with PF. Particular attention was given to diagnostic strategies and the appropriate use of imaging modalities. Treatment efficacies were compared, and potential adverse effects were also discussed. Conclusions: Multiple therapies for PF show similar efficacy. Conservative management should remain first-line, with surgery considered when nonoperative measures fail. Successful outcomes depend on individualized treatment, patient education, and adherence. Collaboration between orthopedic surgeons and physiotherapists plays a key role in optimizing care.

17 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MMMartyna Musiorska
Martyna Musiorska
JMJulia Mazurek
Julia Mazurek
JKJoanna Kośka
Joanna Kośka
GŁGabriela Łocik
Gabriela Łocik
KMKatarzyna Moliszewska
Katarzyna Moliszewska
MBMichał Błaszkiewicz
Michał Błaszkiewicz
Introduction and purpose: Rathke’s cleft cysts (RCCs) are benign, epithelium-lined lesions located in the sellar or suprasellar region, originating from remnants of Rathke’s pouch. While often asymptomatic and discovered incidentally, RCCs may lead to significant clinical symptoms due to compression of adjacent structures, including the pituitary gland and optic chiasm. The aim of this review is to provide a comprehensive overview of RCCs and emphasize the importance of accurate diagnosis and individualized management, especially in symptomatic cases. Material and methods: The review is based on scientific literature published between 2005 and 2025, retrieved from PubMed, Scopus and Google Scholar using the following keywords: “Rathke’s cleft cyst,”, “Rathke’s cyst diagnosis,” “Rathke’s cyst treatment,” “pituitary cyst surgery,” and “Rathke’s cyst recurrence”. Results: Analysis of the literature indicates that although most RCCs remain asymptomatic, a significant subset causes symptoms such as headaches, visual disturbances, and endocrine dysfunction. MRI remains the most effective diagnostic tool, while treatment typically involves transsphenoidal surgical drainage. Recurrence rates vary depending on the surgical technique and inflammatory changes within the cyst wall. Emerging approaches, such as steroid-eluting stents, show promise in reducing recurrence, though further research is needed. Conclusions: RCCs, though generally benign, may result in substantial morbidity in symptomatic patients. Accurate diagnosis, appropriate imaging, and tailored treatment are essential for optimal outcomes. Long-term follow-up is recommended due to the potential for recurrence, and novel interventions offer promising avenues for future management strategies.

26 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ANAlicja Nowik
Alicja Nowik
JMJulia Mazurek
Julia Mazurek
JKJoanna Kośka
Joanna Kośka
JZJulia Załęcka
Julia Załęcka
KMKatarzyna Moliszewska
Katarzyna Moliszewska
MMMartyna Musiorska
Martyna Musiorska
Hereditary angioedema (HAE) is a condition characterized by recurrent edema caused by the dysfunction of bradykinin production. Advances in understanding the pathophysiology of this disease have changed the diagnostic approach, acute management and prophylaxis. Optimal treatment now combines early diagnosis, targeted therapy and patient education. This narrative review provides an overview of current evidence regarding the clinical presentation, treatment options and promising new therapies for HAE. A systematic search of the PubMed and Google Scholar databases was conducted using terms such as hereditary angioedema, therapeutics, C1 inhibitor deficiency, bradykinin and disease management. Additional relevant studies were identified by manually reviewing reference lists and citations. The basis for effective treatment is an accurate diagnosis based on clinical symptoms, family history, and laboratory test results. On-demand treatment, such as C1 esterase inhibitor (C1-INH), icatibant, and ecallantide provides rapid symptomatic control. Long-term prophylaxis with agents such as lanadelumab, berotralstat or plasma-derived C1 esterase inhibitor (pdC1-INH) significantly reduces the frequency of attacks and improves patients’ quality of life. New data confirm that modern biologic therapies can maintain disease control with a favorable safety profile. Current HAE treatment strategies emphasize personalized prophylaxis, adequate intervention in acute attacks and continuous patient education. Combining modern therapies with individual patient preferences improves daily functioning, mental well-being and overall prognosis.

14 July 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
PKPaweł Kukiełka
Paweł Kukiełka
KMKatarzyna Moliszewska
Katarzyna Moliszewska
JKJoanna Kośka
Joanna Kośka
KDKacper Dywan
Kacper Dywan
MBMichał Błaszkiewicz
Michał Błaszkiewicz
GŁGabriela Łocik
Gabriela Łocik
Background:Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously classified under non-alcoholic fatty liver disease (NAFLD), is an increasingly prevalent chronic liver disorder tightly linked to obesity, insulin resistance, and systemic metabolic dysfunction. It ranges from simple steatosis to nonalcoholic steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Objective:This review explores the current understanding of MASLD, emphasizing its multifactorial etiology, evolving pathophysiological mechanisms, clinical progression, and therapeutic strategies, including emerging pharmacological and lifestyle interventions. Methods:A structured review of peer-reviewed articles published between 2019 and 2025 was conducted using critical analysis of uploaded and curated literature focusing on MASLD’s pathogenesis, comorbidities, and treatment modalities. Findings:MASLD is driven by a combination of genetic, environmental, metabolic, and immunological factors. Recent insights into lipid dysregulation, gut-liver axis, immune modulation, and endocrine pathways have clarified mechanisms of disease progression. Weight loss remains a cornerstone of management, supported by emerging anti-obesity medications such as GLP-1 receptor agonists and dual agonists. Novel therapies targeting hepatic stellate cells, fibroinflammatory signaling, and microbiota-derived metabolites represent future avenues for precision-based treatment. Conclusion:Effective MASLD management necessitates an integrated approach combining lifestyle interventions, pharmacotherapy, and targeted therapeutics based on individual phenotypes. Continued research into molecular pathways and personalized strategies holds promise for disease reversal and improved patient outcomes.

13 July 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
KMKatarzyna Moliszewska
Katarzyna Moliszewska
PKPaweł Kukiełka
Paweł Kukiełka
JKJoanna Kośka
Joanna Kośka
GŁGabriela Łocik
Gabriela Łocik
JMJulia Mazurek
Julia Mazurek
MBMichał Błaszkiewicz
Michał Błaszkiewicz
BackgroundThe human gut microbiome—a dynamic ecosystem of bacteria, viruses, fungi, and archaea—is integral to digestion, immune modulation, metabolism, and systemic health. Its composition is shaped by perinatal factors, genetics, environment, diet, physical activity, and probiotic interventions. Modulating the microbiome through lifestyle and nutritional strategies offers potential for disease prevention and enhanced athletic performance. AimThis review synthesizes current evidence on factors influencing gut microbiota composition across the lifespan, the systemic impacts of dysbiosis, and the roles of diet, physical activity, and probiotics—particularly in athletic populations—in fostering a health-promoting microbiome. Material and MethodsA narrative review was conducted using peer-reviewed studies, meta-analyses, and clinical trials sourced from PubMed, Scopus, and Web of Science. Topics included microbiome development, lifestyle and dietary influences, exercise-related microbiome adaptations, and probiotic applications. ResultsPerinatal factors such as delivery mode, breastfeeding, and antibiotics shape early microbiota with long-term health effects. Diet is a primary modulator: fiber- and polyphenol-rich diets enhance microbial diversity, whereas high-protein, low-fiber diets may impair gut health in athletes. Physical activity modifies microbiota structure and function; regular exercise promotes beneficial SCFA-producing taxa, strengthens gut barrier integrity, and supports immune and neurocognitive health. Probiotic supplementation improves gastrointestinal and dermatological conditions, modulates inflammation, and enhances athletic recovery and resilience. ConclusionsThe gut microbiome is a key determinant of systemic health. Targeted diet, structured physical activity, and personalized probiotic use can optimize microbiota function. In athletes, integrating microbiome profiling with individualized nutrition may enhance performance and recovery.

18 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Błaszkiewicz
Michał Błaszkiewicz
JKJoanna Kośka
Joanna Kośka
GŁGabriela Łocik
Gabriela Łocik
KMKatarzyna Moliszewska
Katarzyna Moliszewska
PKPaweł Kukiełka
Paweł Kukiełka
MMMartyna Musiorska
Martyna Musiorska
Objective: Alcoholic cardiomyopathy (ACM) is a dilated cardiomyopathy resulting from chronic excessive alcohol consumption and is a preventable cause of heart failure. While moderate drinking was once thought to reduce cardiovascular risk, recent evidence suggests no safe threshold for ethanol intake. ACM typically develops after prolonged high-dose consumption, often >80 g/day for at least five years, though women may be affected at lower exposure. This review synthesizes epidemiological data, pathophysiology, clinical features, and therapeutic strategies related to ACM. Methodology: This review synthesizes current evidence on ethanol’s cardiac effects and its role in ACM. A narrative synthesis of English-language studies from PubMed and Web of Science was performed, prioritizing systematic reviews, meta-analyses, randomized controlled trials, and large observational studies. Search terms included “alcoholic cardiomyopathy”, “cardiomyopathy”, “ethanol”, “alcohol”, and “heart failure”. Relevant studies were screened and qualitatively analyzed. Key findings: Alcohol induces oxidative stress, mitochondrial dysfunction, impaired calcium handling, and disruption of sarcomeric proteins, culminating in progressive ventricular dilation, contractile dysfunction, fibrosis, and arrhythmias. Clinically, ACM progresses from asymptomatic ventricular dilation to overt systolic heart failure. Women are more susceptible, developing ACM at lower cumulative alcohol exposure than men. Conclusion: ACM represents a preventable cause of heart failure, with early detection and alcohol cessation as critical components for improved outcomes. Public health efforts to reduce harmful drinking remain essential to decreasing ACM incidence and its cardiovascular burden.